Treatment of benign prostate enlargement

At the end of November 2019, the report of the project OTCA17, titled “Lithium triborate (LBO) laser for photoselective vaporization of the prostate (PVP) in the treatment of benign prostatic hyperplasia (BPH)” was published on the website of the European Network for HTA (EUnetHTA).

The report presents a summary of the reimbursement situation for use of minimally invasive treatment of benign prostate enlargement in Europe. The following procedures will be considered under the scope of analysis: transurethral microwave thermotherapy (TUMT), Holmium laser enucleation of the prostate (HoLEP), photoselective vaporization of the prostate, high intensity focused ultrasound (HIFU), Urolift, transurethral resection of the prostate (TURP) as a comparator. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland. It is also possible to add analysis in the Czech Republic, Finland, Hungary, Romania, Russia and Turkey.